Wedbush Issues Negative Outlook for PepGen Earnings

Key Points

• Wedbush has downgraded its Q3 2025 earnings per share estimate for PepGen to ($0.75), a decrease from the previous estimate of ($0.73), while maintaining an "Outperform" rating and a target price of $9.00.
• The consensus estimate for PepGen's full-year earnings is ($2.73), with predictions indicating continued losses through FY2029.
• Recent insider activity includes a major shareholder acquiring 200,000 shares at $3.20 each, increasing their position in the company by 4.21%.

PepGen, Inc. (NASDAQ:PEPG - Free Report) - Research analysts at Wedbush dropped their Q3 2025 earnings per share (EPS) estimates for PepGen in a research report issued on Tuesday, September 30th. Wedbush analyst L. Chico now forecasts that the company will earn ($0.75) per share for the quarter, down from their previous forecast of ($0.73). Wedbush currently has a "Outperform" rating and a $9.00 target price on the stock. The consensus estimate for PepGen's current full-year earnings is ($2.73) per share. Wedbush also issued estimates for PepGen's Q4 2025 earnings at ($0.35) EPS, FY2025 earnings at ($2.44) EPS, Q1 2026 earnings at ($0.35) EPS, Q2 2026 earnings at ($0.36) EPS, Q3 2026 earnings at ($0.32) EPS, Q4 2026 earnings at ($0.32) EPS, FY2026 earnings at ($1.34) EPS, FY2027 earnings at ($1.23) EPS, FY2028 earnings at ($1.20) EPS and FY2029 earnings at ($0.06) EPS.

Several other research analysts have also recently weighed in on PEPG. Stifel Nicolaus upped their price objective on shares of PepGen from $9.00 to $12.00 and gave the stock a "buy" rating in a research report on Thursday, September 25th. Guggenheim restated a "buy" rating and issued a $6.00 price objective on shares of PepGen in a research report on Wednesday, September 24th. Finally, HC Wainwright upped their price objective on shares of PepGen from $8.00 to $12.00 and gave the stock a "buy" rating in a research report on Thursday, September 25th. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $8.40.

PepGen Trading Up 1.9%

PEPG stock opened at $4.71 on Thursday. The company's 50 day moving average is $1.78 and its 200 day moving average is $1.54. The stock has a market cap of $154.49 million, a price-to-earnings ratio of -1.59 and a beta of 1.92. PepGen has a 1-year low of $0.88 and a 1-year high of $9.94.

PepGen (NASDAQ:PEPG - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.70) earnings per share for the quarter, topping the consensus estimate of ($0.85) by $0.15.

Insider Activity at PepGen

In other news, major shareholder Science Enterprises Plc Oxford acquired 200,000 shares of the stock in a transaction dated Tuesday, September 30th. The stock was purchased at an average cost of $3.20 per share, with a total value of $640,000.00. Following the completion of the purchase, the insider owned 4,955,388 shares in the company, valued at approximately $15,857,241.60. The trade was a 4.21% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 5.20% of the company's stock.

Institutional Trading of PepGen

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PEPG. XTX Topco Ltd purchased a new position in PepGen during the first quarter valued at $25,000. ADAR1 Capital Management LLC bought a new position in shares of PepGen during the first quarter valued at $29,000. Rangeley Capital LLC increased its holdings in shares of PepGen by 133.3% during the second quarter. Rangeley Capital LLC now owns 35,000 shares of the company's stock valued at $39,000 after acquiring an additional 20,000 shares in the last quarter. Marshall Wace LLP bought a new position in shares of PepGen during the second quarter valued at $44,000. Finally, Wellington Management Group LLP increased its holdings in shares of PepGen by 17.2% during the fourth quarter. Wellington Management Group LLP now owns 47,506 shares of the company's stock valued at $180,000 after acquiring an additional 6,989 shares in the last quarter. Hedge funds and other institutional investors own 58.01% of the company's stock.

About PepGen

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.